Early treatment of XXXX with intravenous streptokinase. A high-risk syndrome.

@entity1 @entity712 @entity63 @entity1188 @entity951 @entity583
Fifty-one successive @entity1 treated with intravenous streptokinase 1.7 +/- 0.8 (mean +/- SD) hours after onset of symptoms of @entity583 were evaluated during a three-month posthospital follow-up period. Coronary angiography was performed four to nine days after the initial hospital admission. Twenty-eight @entity1 had a second late angiogram. Forty-one @entity1 had successful reperfusion but only 25% of all @entity1 were without significant clinical cardiovascular manifestations during this period. @entity1188 @entity951 occurred in 21 @entity1 , an abnormal stress test result was present in 28 @entity1 , eight @entity1 developed @entity712 , and five @entity1 had reinfarction. An intervention with percutaneous transluminal coronary angioplasty or coronary artery bypass graft was performed in 15 (37%) of 41 reperfused @entity1 . A significantly higher intervention rate was present in @entity1 treated with streptokinase within one hour following the onset of symptoms. Early reocclusion (within three months of the @entity1188 ) was noted in @entity1 with 60% or more residual stenosis in their @entity1188 -related coronary artery. These @entity1 also had a significantly greater incidence of @entity951 . Our findings indicate that early thrombolytic therapy of @entity583 preserves myocardium, and since the @entity1188 is patent, but narrowed, the jeopardized area is responsible for a high-risk syndrome with an increased likelihood of @entity63 symptoms. An early aggressive approach may be indicated, especially for @entity1 with greater than 60% residual stenosis in their @entity1188 -related coronary artery.
